Skip to main content

Table 3 Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type

From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

 

CR

PR

SD

PD

p value

Total (n = 363)

1 (0.3)

265 (73.0)

72 (19.8)

25 (6.9)

 

E19del (n = 175)

    

0.785

 Afatinib (n = 53)

0

38 (71.7)

12 (22.6)

3 (5.7)

 

 Erlotinib (n = 69)

1 (1.4)

54 (78.3)

10 (14.5)

4 (5.8)

 

 Gefitinib (n = 53)

0

40 (75.5)

11 (20.8)

2 (3.8)

 

L858R (n = 154)

    

0.471

 Afatinib (n = 38)

0

30 (78.9)

6 (15.8)

2 (5.3)

 

 Erlotinib (n = 61)

0

42 (68.9)

15 (24.6)

4 (6.6)

 

 Gefitinib (n = 55)

0

45 (81.8)

9 (16.4)

1 (1.8)

 

Uncommon (n = 34)

    

0.332

 Afatinib (n = 11)

0

6 (54.5)

3 (27.3)

2 (18.2)

 

 Erlotinib (n = 9)

0

4 (44.4)

4 (44.4)

1 (11..1)

 

 Gefitinib (n = 14)

0

6 (42.9)

2 (14.3)

6 (42.9)

 
  1. Data are shown as n (%) per each group
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations